Medical device manufacturers could pay up to double in the next 5 years to FDA . In exchange, they hope to see quicker approvals and better communications from FDA. The current program requires about half of that amount and expires September 30, 2012. FDA may bring on up to 200 new hires to speed things up. To learn more, click here.
Obstacles Facing Biosimilars
Still in its infancy in the U.S., the industry faces some growing pains.
Life Science Accelerated
Our experts are dedicated to expediting life science product development regulatory pathways.